CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease

Laura H Mariani, Andrew S Bomback, Pietro A Canetta, Michael F Flessner, Margaret Helmuth, Michelle A Hladunewich, Jonathan J Hogan, Krzysztof Kiryluk, Patrick H Nachman, Cynthia C Nast, Michelle N Rheault, Dana V Rizk, Howard Trachtman, Scott E Wenderfer, Corinna Bowers, Peg Hill-Callahan, Maddalena Marasa, Caroline J Poulton, Adelaide Revell, Suzanne Vento, Laura Barisoni, Dan Cattran, Vivette D'Agati, J Charles Jennette, Jon B Klein, Louis-Philippe Laurin, Katherine Twombley, Ronald J Falk, Ali G Gharavi, Brenda W Gillespie, Debbie S Gipson, Larry A Greenbaum, Lawrence B Holzman, Matthias Kretzler, Bruce Robinson, William E Smoyer, Lisa M Guay-Woodford, CureGN Consortium

Am J Kidney Dis. 2019 Feb 1; 73(2):218-229


Study design: Multicenter prospective cohort study. Setting & participants: Cure Glomerulonephropathy (CureGN) will enroll 2,400 children and adults with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (including IgA vasculitis) and a first diagnostic kidney biopsy within 5 years. Patients with ESKD and those with secondary causes of glomerular disease are excluded. Exposures: Clinical data, including medical history, medications, family history, and patient-reported outcomes, are obtained, along with a digital archive of kidney biopsy images and blood and urine specimens at study visits aligned with clinical care 1 to 4 times per year. Outcomes: Patients are followed up for changes in estimated glomerular filtration rate, disease activity, ESKD, and death and for nonrenal complications of disease and treatment, including infection, malignancy, cardiovascular, and thromboembolic events. Analytical approach: The study design supports multiple longitudinal analyses leveraging the diverse data domains of CureGN and its ancillary program. At 2,400 patients and an average of 2 years' initial follow-up, CureGN has 80% power to detect an HR of 1.4 to 1.9 for proteinuria remission and a mean difference of 2.1 to 3.0mL/min/1.73m2 in estimated glomerular filtration rate per year. Limitations: Current follow-up can only detect large differences in ESKD and death outcomes. Conclusions: Study infrastructure will support a broad range of scientific approaches to identify mechanistically distinct subgroups, identify accurate biomarkers of disease activity and progression, delineate disease-specific treatment targets, and inform future therapeutic trials. CureGN is expected to be among the largest prospective studies of children and adults with glomerular disease, with a broad goal to lessen disease burden and improve outcomes.

Read More on PubMed